Sandra Boenisch - 02 Jan 2024 Form 4 Insider Report for ANAVEX LIFE SCIENCES CORP. (AVXL)

Role: PFO & Treasurer
Signature: /s/ Sandra Boenisch
Issuer symbol: AVXL
Transactions as of: 02 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 12 Jan 2024, 20:00:34 UTC
Previous filing: 04 Aug 2021
Next filing: 06 Dec 2024
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AVXL	Stock Option (Right to Buy)	Award	$0	+10,000		$0.000000	10,000	02 Jan 2024	Common Stock	10,000	$10.09	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Sandra Boenisch is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	On June 27, 2022, the reporting person was granted an option to purchase 40,000 shares of common stock. The option vests in four equal tranches based on four performance milestones, one of which included topline data readout of ANAVEX2-73-RS-003 EXCELLENCE clinical trial in Rett Syndrome. The performance criteria for this milestone was met, resulting in vesting of the option as to 10,000 shares.